The shareholder vote removes the last major regulatory/approval hurdle for the AbbVie acquisition. The deal is now subject to remaining antitrust clearances (Australia ACCC) and customary closing conditions. Traders should monitor for the final regulatory sign-offs and the expected closing date; the stock should trade near the $135.11 offer price minus any remaining risk premium.
Price Chart
Executive Summary
Apogee Therapeutics stockholders voted overwhelmingly to approve the $135.11/share all-cash acquisition by AbbVie, with 46,508,107 votes for and only 3,885 against, satisfying a key closing condition. The board also disclosed that all seven directors intend to resign effective at the merger's closing, a routine step in a change-of-control transaction. The non-binding advisory vote on executive merger-related compensation was rejected, but this does not affect deal consummation. The merger remains on track with German antitrust clearance already obtained and an Australian filing underway.
Key Facts
- Stockholders approved the merger proposal with 46,508,107 votes for, 3,885 against, and 14,261 abstentions.
- All seven directors (Michael Henderson, Mark C. McKenna, Lisa Bollinger, Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak, Nimish Shah) intend to resign effective at the merger closing.
- The non-binding advisory vote on executive merger compensation was not approved (19,323,605 for, 27,123,259 against), but this is not a condition to closing.
- The merger is an all-cash acquisition by AbbVie at $135.11 per share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.
- German antitrust clearance (FCO) was obtained on July 27, 2026, and an Australian ACCC filing is underway.
Financial Impact
All-cash acquisition at $135.11/share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.
Risk Factors
- Remaining antitrust clearances (Australia ACCC) could delay closing.
- The non-binding compensation vote rejection signals potential shareholder dissent, though it does not block the deal.
- Any unexpected regulatory or litigation developments could delay or derail the merger.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032231 |
| Document: 0001140361-26-032231-index-headers.html | 0001140361-26-032231 |
| Document: 0001140361-26-032231-index.html | 0001140361-26-032231 |
| Document: 0001140361-26-032231.txt | 0001140361-26-032231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access